Scientists reveal a new therapeutic vulnerability in pancreatic cancer

(Columbia University Irving Medical Center) Reducing levels of a hormone prevented metastasis and prolonged survival in mice with pancreatic cancer, a study from Columbia has found, which could lead to new treatments for patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Conditions:   Pancreatic Ductal Adenocarcinoma;   Pancreas Cancer Intervention:   Drug: S-1, leucovorin, oxaliplatin and gemcitabine Sponsor:   National Health Research Institutes, Taiwan Recruiting
Source: - Category: Research Source Type: clinical trials
Contributors : Hewei Zhang ; Lijun Kong ; Cheng Wang ; Linxiao SunSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMaslinic acid (MA) is a triterpenoid compound of natural abundance in olive plants possessing numerous biological activities. The effect and molecular mechanism of MA on pancreatic cancer cells remain elusive. Here, we explored the anti-tumor activity of MA on human pancreatic cancer cells and the potential underlying molecular mechanism. The anti-cancer effects of MA on whole-cell processes, including proliferation, migration, and invasion in pancreatic cancer cells, were...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
In conclusion, there was no difference in clinical characteristics according to the timing of distant metastasis. Oncological outcomes differed by metastatic site.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
ConclusionA trajectory optimization algorithm was developed for non-coplanar VMAT. Compared with conventional coplanar VMAT, non-coplanar VMAT resulted in improved coverage and conformity to the targets. The sparing of OARs was significantly improved in non-coplanar VMAT compared with coVMAT plans for locally advanced pancreatic cancer.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Collectively, these data demonstrated that m6A modification participates pancreatic cancer progress and ornaments immune microenvironment, providing an insight into pancreatic cancer pathogenesis and facilitating precision medicine development.
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
rquardt Hendrik Ungefroren Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and therapy-resistant cancer types which is largely due to tumor heterogeneity, cancer cell de-differentiation, and early metastatic spread. The major molecular subtypes of PDAC are designated classical/epithelial (E) and quasi-mesenchymal (QM) subtypes, with the latter having the worst prognosis. Epithelial–mesenchymal transition (EMT) and the reverse process, mesenchymal-epithelial transition (MET), are involved in regulating invasion/metastasis and stem cell generation in cancer cells but also early pancreatic en...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
The purpose was aimed to establish a simple computational model to predict tumor prognosis by combining neutrophil to lymphocyte Ratio (NLR) and biomarkers of oncological characteristics in patients undergoing vascular reconstructive radical resection of PDAC. The enrolled patients was divided into high or low NLR group with the cutoff value determined by the receiver operator characteristic (ROC) curve. Different vascular anastomoses were selected according to the Chaoyang classification of PDAC. Survival rates were calculated using the Kaplan-Meier and evaluated with the log-rank test. Cox risk regression model was used ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Imagine a world in which physicians can confidently cure cancer. Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer. “With cancer therapies,…
Source: Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
By HANS DUVEFELT Leo Dufour is not a diabetic. He is in his mid 50s, a light smoker with hypertension and a known hiatal hernia. He has had occasional heartburn and has taken famotidine for a few years along with his blood pressure and cholesterol pills. Over the past few months, he started to experience a lot more heartburn, belching and bloating. Adding pantoprazole did nothing for him. I referred him to a local surgeon who did an upper endoscopy. This did not reveal much, except some retained food in his stomach. A gastric emptying study showed severe gastroparesis. The surgeon offered him a trial of metoclopra...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Medical Practice Physicians Primary Care Hans Duvefelt Source Type: blogs
Pulmonary tumor thrombotic microangiopathy is a fatal disease secondary to some malignant tumors, such as gastric cancer, esophageal cancer, and pancreatic cancer. A 61-year-old man presented to our clinic with a red plaque with erosion on his scrotum and was diagnosed with extramammary Paget ’s disease. Seven years after the initial diagnosis, multiple bone metastases were discovered, and he was started on oral administration of tegafur/gimeracil/oteracil. Two years after beginning the oral drug administration, the patient complained of dyspnea. A chest CT scan showed ground-glass opa city. Pulmonary artery blood cy...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Hormones | Pancreas | Pancreatic Cancer | Study